A5015484380- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Systemic Lupus Erythematosus Research
- SARS-CoV-2 and COVID-19 Research
- Autoimmune and Inflammatory Disorders Research
- Peripheral Neuropathies and Disorders
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Systemic Sclerosis and Related Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Dermatological and COVID-19 studies
- COVID-19 Clinical Research Studies
- Hepatitis C virus research
- Bone and Joint Diseases
- Ocular Diseases and Behçet’s Syndrome
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Infectious Diseases and Tuberculosis
- Long-Term Effects of COVID-19
- Biosimilars and Bioanalytical Methods
- Diabetes and associated disorders
- Transcranial Magnetic Stimulation Studies
- Herpesvirus Infections and Treatments
- Tuberculosis Research and Epidemiology
- Inflammasome and immune disorders
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2015-2025
Universidade de São Paulo
2012-2023
Fundação Faculdade de Medicina
2023
Hospital das Clínicas da Universidade Federal de Minas Gerais
2023
Weatherford College
2023
Instituto Nacional do Câncer
2023
Universidade Federal de Lavras
2023
Universidade Federal de São Paulo
2021-2023
Economie Publique
2023
Center for Rheumatology
2021-2022
Objective To evaluate the effect on immunogenicity and safety of 2-week methotrexate (MTX) discontinuation after each dose Sinovac-CoronaVac vaccine versus MTX maintenance in patients with rheumatoid arthritis (RA). Methods This was a single-centre, prospective, randomised, investigator-blinded, intervention study ( NCT04754698 , CoronavRheum) including adult RA (stable Clinical Disease Activity Index (CDAI) ≤10, prednisone ≤7.5 mg/day) randomised (1:1) to withdraw (MTX-hold) for 2 weeks or...
Objective To determine the immunogenicity of third dose CoronaVac vaccine in a large population patients with autoimmune rheumatic diseases (ARD) and factors associated impaired response. Methods Adult ARD age-balanced/sex-balanced controls (control group, CG) previously vaccinated two doses received at D210 (6 months after second dose). The presence anti-SARS-CoV-2 S1/S2 IgG neutralising antibodies (NAb) was evaluated to vaccination (D210) 30 days later (D240). Patients controlled disease...
To evaluate the influence of abatacept (ABA) and associated contributing factors on pandemic 2009 influenza A/H1N1 vaccine immunogenicity in rheumatoid arthritis (RA) patients.The response to a nonadjuvanted monovalent killed virus was analyzed 11 RA patients using ABA (RA-ABA), most with concomitant nonbiologic disease-modifying antirheumatic drugs (DMARDS), compared 33 age-matched methotrexate (MTX) 55 healthy controls, all without previous seroprotection. Clinical laboratory evaluations...
Background Despite the WHO recommendation that 2010–2011 trivalent seasonal flu vaccine must contain A/California/7/2009/H1N1-like virus there is no consistent data regarding its immunogenicity and safety in a large autoimmune rheumatic disease (ARD) population. Methods 1668 ARD patients (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic sclerosis, psoriatic (PsA), Behçet's (BD), mixed connective tissue disease, primary antiphospholipid...
<h3>Background</h3> Reduced response to pandemic (2009) H1N1 (pH1N1) vaccine in patients with rheumatoid arthritis (RA) was recently reported. <h3>Objectives</h3> To evaluate the contribution of age, disease activity, medication and previous antibody levels this reduced response. <h3>Methods</h3> 340 adult RA 234 healthy controls were assessed before 21 days after adjuvant-free influenza A/California/7/2009 vaccine. Disease activity (DAS28), current treatment pH1N1 titres collected....
Objective. To assess the immunogenicity and safety of non-adjuvanted influenza A H1N1/2009 vaccine in patients with juvenile autoimmune rheumatic disease (ARD) healthy controls, because data are limited to adult rheumatologic population. Methods. total 237 ARD [juvenile systemic lupus erythematosus (JSLE), idiopathic arthritis (JIA), dermatomyositis (JDM), scleroderma, vasculitis] 91 controls were vaccinated. Serology for anti-H1N1 was performed by hemagglutination inhibition assay....
Objective. To evaluate the immunogenicity of anti-influenza A H1N1/2009 vaccine in RA and spondyloarthritis (SpA) patients receiving distinct classes anti-TNF agents compared with DMARDs healthy controls. Methods. One hundred twenty (RA, n = 41; AS, 57; PsA, 22) on (monoclonal, 94; soluble receptor, 26) were 116 inflammatory arthritis under 117 Seroprotection, seroconversion (SC), geometric mean titre, factor increase titre adverse events evaluated 21 days after vaccination. Results. After...
Objective. To assess the efficacy and safety of pandemic 2009 influenza A (H1N1) in SLE under different therapeutic regimens. Methods. total 555 patients 170 healthy controls were vaccinated with a single dose non-adjuvanted preparation. According to current therapy, initially classified as No Therapy ( n = 75) 480). Subsequent evaluations included groups monotherapy: chloroquine (CQ) 105), prednisone (PRED) ≥20 mg 76), immunosuppressor (IS) 95) those combination these drugs. Anti-H1N1...
To date, the only study that has assessed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but sample size precluded an accurate analysis of effect individual drugs. Therefore, we evaluated immunogenicity inactivated SARS-CoV-2 (Sinovac-CoronaVac) and influence different medications SLE. Safety was also assessed.We conducted prospective controlled 232 SARS-CoV-2-naive SLE patients 58 controls who...
Objectives To evaluate the distinct impact of disease modifying antirheumatic drugs (DMARD) combination and monotherapy in immune response to an inactivated SARS-CoV-2 vaccine patients with rheumatoid arthritis (RA). Methods This phase 4 prospective study analysed seroconversion (SC) anti-SARS-CoV-2 immunoglobulin G (IgG) neutralising antibodies (NAb) induced by (CoronaVac) RA comparison controls (CG). Disease activity treatment were also assessed. Only participants baseline negative IgG/NAb...
Objectives To investigate factors associated with severe COVID-19 in people psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Methods Demographic data, clinical characteristics outcome severity of adults PsO, PsA axSpA were obtained from two international physician-reported registries. A three-point ordinal scale was defined: no hospitalisation, hospitalisation (and death) death. ORs estimated using multivariable logistic regression. Results Of 5045 cases, 18.3%...
Background: Advances in pathophysiology and treatment of ankylosing spondylitis (AS) was recently demonstrated.However, the effect anti-TNF newly described inflammatory pathways involved pathogenesis this disease remains to be determined.The aim our study was, therefore, investigate long-term influence drugs IL-23/IL-17 axis AS patients their possible correlation with treatment, clinical, laboratory radiographic parameters.Methods: Eighty-six naïve patients, 47 referred for therapy...
We aimed to examine the immunogenicity pattern induced by inactivated SARS-CoV-2 vaccine CoronaVac (Sinovac Life Sciences, Beijing, China) in seropositive patients with autoimmune rheumatic diseases compared controls, seronegative diseases, and controls.
Background Immunosuppressed individuals present serious morbidity and mortality from influenza, therefore it is important to understand the safety immunogenicity of influenza vaccination among them. Methods This multicenter cohort study evaluated reactogenicity an inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine elderly, HIV-infected, rheumatoid arthritis (RA), cancer, kidney transplant, juvenile idiopathic (JIA) patients. Participants were included during routine...
Recommendations for screening latent tuberculous infection (LTBI) in patients eligible anti-tumour necrosis factor (TNF) agents remain unclear endemic regions.To evaluate the long-term efficacy of LTBI and treatment with rheumatoid arthritis (RA) receiving TNF blockers.A total 202 RA were screened before anti-TNF using tuberculin skin test (TST), chest X-ray (CXR) history exposure to tuberculosis (TB). All subjects regularly followed at 1- 3-month intervals.Eighty-five (42%) treated a single...
Abstract Objectives To assess immunogenicity of a heterologous fourth dose an mRNA (BNT162b2) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in autoimmune rheumatic diseases (ARD) patients with poor/non-response to inactivated (Sinovac-CoronaVac). Methods A total 164 ARD who were disease 2019 (COVID-19) poor/non-responders (negative anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies—NAb) the third Sinovac-CoronaVac received additional 3 months after last dose. and...
Aim: The use of anti-TNF drugs is well-established for treating axial spondyloarthritis (axSpA). introduction biosimilars offers a more accessible alternative, but data on the switching adalimumab in axSpA population remain somewhat controversial and are limited to SB5 ABP 501 European population. This study aims evaluate clinical efficacy from originator biosimilar adalimumab-AACF Latin American patients over 12-month period real-life analysis. Methods: observational included with who had...
El artículo aborda una primera reflexión respecto de la posibilidad identificar situación vulnerabilidad como un bien jurídico protegido, encontrando los puntos en común distintas situaciones humanas que pueden presentarse a lo largo vida, focalizando alguna éstas, niñez y adolescencia, las personas mayores discapacidad.
Patients with autoimmune rheumatic diseases (ARDs) are at an increased risk for herpes zoster (HZ). Vaccination is recommended this population. The aim of study was to evaluate the safety vaccination recombinant vaccine (Shingrix) in ARD patients, humoral immunogenicity (HI), cellular (CI), and incidence HZ. This randomized, double-blind, placebo-controlled phase 4 involves 1180 patients a control group (CG) 393 balanced healthy individuals, aged ≥50 years. will be randomly assigned blinded...
Student career management is a critical activity in the education sector. Machine learning method, Recursive Feature Elimination (RFE), has been used to find key features for prediction tasks with help of Students’ data. Using RFE, which machine technique, massive datasets are analyzed, and most pertinent chosen predictions, increasing computing speed accuracy. RFE combined several techniques feature selection, such as support vector machines (SVM), decision trees, random forests, many more....